Navigation Links
FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial
Date:3/9/2011

SEATTLE, March 10, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced the final clinical trial design of a randomized pivotal trial of pixantrone for the treatment of diffuse large B-cell lymphoma ("DLBCL") following discussions with the  U.S. Food and Drug Administration's (the "FDA") Division of Hematologic Products (the "DHP") .  The new clinical trial, referred to as the PIX-R or PIX 306 trial, will compare a combination of pixantrone plus rituximab to a combination of gemcitabine plus rituximab in patients with relapsed or refractory DLBCL who have received one to three prior lines of therapy, utilizing progression free survival ("PFS") and Overall Survival ("OS")as co-primary endpoints of the study. The PIX-R trial, is targeting to enroll approximately 350 patients over 18 months and will include patients who have failed at least one line of previous therapy and patients who are not candidates for myeloablative chemotherapy and stem cell transplant. During its discussions with the DHP the Company was advised that only OS would be acceptable for a formal Special Protocol Assessment ("SPA") agreement, however the DHP noted that the Company could conduct a study utilizing PFS along with OS as co-primary endpoints which would be an acceptable design outside of the formal SPA process. Regulatory acceptability will depend on the magnitude of the difference between the trial study arms as well as a risk and benefit analysis.

"CTI has worked with the DHP since August on an appropriate clinical trial design that may serve as either a post-marketing commitment trial or as a follow-on pivotal trial depending on the outcome of an appeal of CTI's new drug application for pixantrone based on the PIX 301 trial at the FDA's Office of New Drugs," stated James A. Bianco, M.D., CEO of Cell Therapeutics.

"We believe that pre-clinical data and results from a randomized clinical trial have already demonstrated syn
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
2. China-Biotics, Inc. Provides Preliminary FY2011Third Quarter Revenue
3. Savient Pharmaceuticals Provides Business Update
4. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
5. Celsion Reports Third Quarter 2010 Financial Results and Provides Business Update
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
7. Generex Provides Additional Details for October 21st Live Video Webcast
8. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
9. PDL BioPharma Provides Clarification Regarding Redemption of Its 2.75% Convertible Subordinated Notes
10. PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
11. NeoStem Provides Second Quarter Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015  Caris Life Sciences® today announced ... which researchers utilized Caris Molecular Intelligence®, the company,s ... therapeutic targets in patients with colorectal and pancreatic ... cell death protein 1 (PD-1) and its ligand, ... the 2015 American Society of Clinical Oncology Annual ...
(Date:5/29/2015)... Seoul Semiconductor (CEO: Chung-hoon Lee, ... on May 28th announced that it will increase ... its high efficient and high reliable LED product ... Seoul Semiconductor has developed efficient and reliable LED ... supplied LEDs for headlamps to global auto makers. ...
(Date:5/28/2015)... DUBLIN , May 28, 2015 ... Markets ( http://www.researchandmarkets.com/research/8h5hs2/animal ) has announced the ... "Animal Biotechnology - Technologies, Markets and ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This report describes and ... in veterinary medicine and pharmaceuticals as ...
(Date:5/28/2015)... The Academy of Model Aeronautics Foundation will be celebrating the ... National Model Aviation Day was created to celebrate the hobby ... the general public. , The AMA has encouraged all of ... by hosting events in their own communities. More than 80 ... View our online event map to find an event ...
Breaking Biology Technology:Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Model flying pilots celebrate the Academy of Model Aeronautics Foundation’s Third Annual National Model Aviation Day 2
... Mass., Jan. 4, 2011 Interleukin Genetics, Inc. (OTC ... will present at the Biotech Showcase 2011, taking place ... 2011.  The corporate presentation will include a company overview ... January 10 at 3:45 p.m. in the Mission II ...
... 4, 2011 Reportlinker.com announces that a new ... Emerging Opportunities in Biosimilar and ... Executive SummaryThe biosimilar and ... in a grand manner following a series of ...
... Reportlinker.com announces that a new market research ... Financial Health of Biotechnology and Drugs Industry ... http://www.reportlinker.com/p0357094/Financial-Health-of-Biotechnology-and-Drugs-Industry-in-India-and-China.html The research services examines ... companies across 2 broad parameters- Excellence in financial ...
Cached Biology Technology:Interleukin Genetics, Inc. to Present at Biotech Showcase 2011 2Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets 2Reportlinker Adds Financial Health of Biotechnology and Drugs Industry in India and China 2
(Date:5/19/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/14/2015)... NEW YORK , May 14, 2015 ... specializing in identity verification and online remote ... Instructure, a software-as-a-service (SaaS) company and creator ... Shared customers of the two companies will ... Proctortrack in Canvas. As a ...
(Date:5/8/2015)... SAN JOSE, Calif. , May 8, 2015 ... human interface solutions, today announced that members of the executive ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Westin Waterfront Hotel in Boston, MA ... Date: May 27, 2015 Time: 2:45pm ET Location: The New ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2
... Society of America (ESA) is proud to announce its ... Fellow acknowledges outstanding contributions in research, teaching, extension, or ... ESA Annual Meeting, which will be held from November ... Dr. Robert N. Coulson has ...
... of all life on earth, yet freshwater animals and ... ecosystem. The dominant causes are the many stressors ... over-fishing, invasions by alien species, dams, over-abstraction, many forms ... also highly sensitive to climate change which now exacerbates ...
... have suffered a stroke or who have been diagnosed ... Queen,s University Belfast. Dr Cathy Craig from Queen,s ... sensory devices for those who normally have difficulty controlling ... a grant of 860,924 from the European Research Council. ...
Cached Biology News:Entomological Society of America names new Fellows for 2008 2Entomological Society of America names new Fellows for 2008 3Entomological Society of America names new Fellows for 2008 4Entomological Society of America names new Fellows for 2008 5Entomological Society of America names new Fellows for 2008 6Entomological Society of America names new Fellows for 2008 7Entomological Society of America names new Fellows for 2008 8Entomological Society of America names new Fellows for 2008 9Entomological Society of America names new Fellows for 2008 10Water: stressed-out and overheated 2New sensory devices will aid Parkinson's and stroke patients 2
Goat polyclonal to Lipocalin 2...
Immunogen for A300-655A was a phosphorylated synthetic peptide, which represented a portion of human RNA Polymerase II (GeneID 5430) around serine 5 of the C-terminal repeat YSPTSPS....
Acetylcholinesterase from human and monkey....
Excellent safety and durability., Remote control can be easily operated in your hand., Constant voltage control with 2 sets of terminals., Precise and durable circuit design. ...
Biology Products: